Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership signifies a major step forward in enhancing colorectal cancer screening and diagnostics within the Italian healthcare system as it enables the implementation of ColoAlert® into Italy's robust healthcare framework, providing patients with access to a cutting-edge diagnostic solution that combines convenience with clinical excellence.

US-based Veracyte has agreed to acquire minimal residual disease (MRD) test developer C2i genomics in a deal worth up to $95m, strengthening its range of cancer diagnostic products.

Oxford Nanopore Technologies PLC (LSE:ONT) has secured a £70 million investment from French in-vitro diagnostics (IVD) company bioMérieux, in exchange for a 3.5% stake.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion of their Global Business Partnership Agreement with Sysmex.

On March 18th, at the 8th E-Trade Bioindustry Conference of 2023EBC, MGI Tech held the "DNBSEQ-G99 Signing Ceremony" and reached cooperation with 6 enterprise partners to develop G99-based application expansion.

Leica Biosystems and Paige announced that they are expanding their previously announced digital pathology partnership. ​

QIAGEN announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).

Illumina and Myriad Genetics said on Thursday that they have expanded their strategic partnership on homologous recombination deficiency (HRD) testing.